Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Isabel Graupera et al.|The Lancet|2019Cited by 1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodRaúl J. Andrade, José Antonio Durán, M. Isabel Lucena et al.|Gastroenterology|2005Cited by 1k
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registryRaúl J. Andrade, Ramón Hidalgo, M. Isabel Lucena et al.|Hepatology|2006Cited by 306
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis GroupSimon Pape, Nanda Kerkar, Romée J.A.L.M. Snijders et al.|Journal of Hepatology|2022Cited by 172